These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12412765)

  • 1. Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.
    Cheung AK; Parker CJ; Wilcox L
    Clin Exp Immunol; 1989 Nov; 78(2):299-306. PubMed ID: 12412765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat.
    Till GO; Morganroth ML; Kunkel R; Ward PA
    Am J Pathol; 1987 Oct; 129(1):44-53. PubMed ID: 3661679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
    von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
    Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment of donor with 1-deamino-8-d-arginine vasopressin could alleviate early failure of porcine xenograft in a cobra venom factor treated canine recipient.
    Kang HJ; Lee G; Kim JY; Lee SH; Wi HC; Hwang PG; Chung DH; Kim YT
    Eur J Cardiothorac Surg; 2005 Jul; 28(1):149-56. PubMed ID: 15982598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
    Eggertsen G; Lundwall A; Hellman U; Sjöquist J
    J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
    Usami M; Ohno Y
    J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
    Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
    Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
    Hodgetts SI; Grounds MD
    Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
    Fu Q; McPhie P; Gowda DC
    Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
    Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
    Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.
    van Dam AP; Hack CE
    Immunology; 1987 Jun; 61(2):105-10. PubMed ID: 3596635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
    Vogel CW; Finnegan PW; Fritzinger DC
    Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naja melanoleuca cobra venom contains two forms of complement-depleting factor (CVF).
    Osipov AV; Mordvintsev DY; Starkov VG; Galebskaya LV; Ryumina EV; Bel'tyukov PP; Kozlov LV; Romanov SV; Doljansky Y; Tsetlin VI; Utkin YN
    Toxicon; 2005 Sep; 46(4):394-403. PubMed ID: 16054663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.